Neogenomics Inc.
NEO
Get informed when a big investor buys or sells
+ FollowMarket Cap$463.79M
Close$
$-9.51
154.5% downside
Current Fair Value
154.5% downsideOvervalued by 154.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $463.79 Million |
|---|---|
| Enterprise Value | $766.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.2 |
| Beta | 1.73 |
| Outstanding Shares | 25,925,600 |
Return
| Return on Equity | -6.60% |
|---|---|
| Return on Assets | -3.84% |
| Return on Invested Capital | -3.65% |
Valuation & Multiples
| P/E Ratio | -9.1 |
|---|---|
| PEG | 8.67 |
| Price to Sales | 0.6 |
| Price to Book Ratio | 0.58 |
| Enterprise Value to Revenue | 1 |
| Enterprise Value to EBIT | -16.87 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.58 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$196.95 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$205.89 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0059▼ 9.69% |
|---|---|
| Total Calls | 9,164,650▲ 998.48% |
| Total Puts | 53,700▼ 37.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 573.66%▲ 52.22% |
|---|---|
| Total Invested | $2.27B▲ 128.42% |
| Investors Holding | 277▲ 17.00% |
ESG Score
No data
About Neogenomics Inc.
1,600 employeesNeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...